Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
Although anagrelide is a widely used therapeutic agent for patients with essential thrombocythemia, the exact mechanism of action is unclear. Immortalized megakaryocyte progenitor cell lines (imMKCLs) were established from human induced pluripotent stem (iPS) cells. Both undifferentiated and differentiated imMKCLs were treated with several different concentrations of anagrelide and followed by mRNA sequencing and some assaying procedures. We successfully reproduced the platelets-lowering effect of anagrelide by using imMKCLs from human iPS cells which could generate functional platelets in vitro. We also demonstrated that anagrelide inhibits the proliferation in undifferentiated imMKCLs through specifically suppressing the megakaryogenesis and platelet-formation related genes, and the maturation in differentiated imMKCLs through the altering of cell cycle related genes.
|